Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Endocrinology and metabolic disorders 2

Endocrinology and Metabolic Disorders

Pharma-news-for-astrazeneca-sanofi-UCB

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Zevra’s MIPLYFFA Niemann-Pick Disease Approval; FASENRA Approved for Eosinophilic Granulomatosis; Sanofi’s SARCLISA Gets Multiple Myeloma Approval; RYBREVANT Combo Gets FDA Nod for EGFR Lung Cancer; UCB’s BIMZELX Receives Multiple Approval from the FDA

FDA Greenlights Zevra Therapeutics’ MIPLYFFA for Niemann-Pick Disease Type C Zevra Therapeutics, Inc. has announced that the FDA has approved MIPLYFFA (arimoclomol) capsules as the first oral treatment for Niemann-Pick disease type C. Indicated for use alongside miglustat, MIPLYFFA is intended for both adult and pediatric patients aged two and older. This approval marks a significant milestone for NPC patients, who previously had no FDA-approved options. Zevra has also received a rare pediatric disease priority review voucher in conjunction with this approval. Neil F. McFarlane, President and CEO of Zevra Therapeutics, emphasized the importance of this approval...

Explore More...

rezdiffra-journey-in-nash-treatment

Empowering Change: REZDIFFRA’s Trailblazing Journey in NASH Treatment

medtech-news-for-insulet-corporation-vericel-pacemate

Insulet Corporation’s Omnipod® 5 Automated Insulin Delivery System Receives FDA Approval; FDA Gives Green Light to Expand Vericel’s MACI Arthro Label; SkinCure Oncology Announces New Study of Non-melanoma Skin Cancer Through Image-guided Superficial Radiation Therapy; SDC’s BYOD ePRO Solution Clinical Trial; PaceMate® Acquires Paceart Optima™ System; KARL STORZ Acquires a US-headquartered Company

yorvipath-for-hypoparathyroidism-treatment

YORVIPATH for Hypoparathyroidism Treatment – The First and Only Therapy for Therapy for Adults

pharma-news-for-ascendis pharma-novartis-servier

FDA Approves Ascendis Pharma’s YORVIPATH; ARS Pharma Gets FDA Green Light for First Nasal Spray; FDA Rejects Lykos’ MDMA-Assisted PTSD Therapy; Novartis’ FABHALTA Receives FDA Accelerated Approval; Servier Snags FDA Approval for Voranigo

pharma-news-for-Adaptimmune-GSK-Otsuka

Tecelra by Adaptimmune: First FDA-Approved Engineered Cell Therapy for Solid Tumors; GSK’s JEMPERLI Approved for Endometrial Cancer; MBX Biosciences Secures $63.5M in Series C for PEP™ Platform; FDA Stops Actinium’s Radiotherapy Blood Cancer Plans, Pushing Partnering Shift; Otsuka Acquires Jnana for Up to $1.1B, Enhancing Drug Discovery

medtech-news-for-stryker-vialase-diamyd-medical

Stryker’s Spine Guidance 5 Software FDA Approval; VIALASE Received CE Mark; The Texas Heart Institute Implanted the BiVACOR® Total Artificial Heart; Diamyd Medical’s Phase 3 Trial Positive Results; Cardio Diagnostics Holdings Inc.’s CDIO.AI; GE Healthcare and AWS Strategic Collaboration

pharma-news-for-valneva-innovent-gsk-bayer

CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy

medtech-news-for-artivion-masimo-icecure

Artivion and Endospan Agreement; Masimo and Cleveland Clinic Collaboration; Academic Medical Center’s Sedation-Free TNE With the EvoEndo Endoscopy System; IceCure’s Next-Gen XSenseTM Cryoablation System FDA Approval; KORU Medical Systems’ Clearance for FreedomEdge® Infusion System; Reflow Medical’s First Patient in Coronary Sirolimus-Eluting Retrievable Scaffold System

transforming-obesity-treatment

The Race to Redefine Obesity Treatment

type-1-diabetes-in-ada-2024

Advances in Type 1 Diabetes (T1D) Treatment: Cutting-Edge Therapies and Innovations Unveiled at ADA 2024

emerging-therapies-for-obesity-in-ada-2024

Beyond GLP-1: Emerging Therapies for Obesity Discussed at ADA 2024

glp-1-receptor-agonists-in-ada-2024

Next-gen GLP-1 Breakthroughs: Revolutionizing Diabetes and Obesity Treatment at ADA 2024

top-highlights-from-ada-conference-2024

Advancing Diabetes Care: Highlights from the ADA’s 84th Scientific Sessions

pharma-news-for-alnylam-bms-daichii-sankyo-vertex

Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval

pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms

Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval

pharma-news-for-moderna-almirall-lilly-ipsen

Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly